MORE ON DR. SHORE
Boards

• Medical Director, Carolina Urologic Research Center, Myrtle Beach, SC, 2000 - present
• Executive Board Member, Linked Urology Research Network, 2001- present
• Executive Board Member, Uropath, LLC, 2003 - present
• Medical Director, US Too, Prostate Cancer Support Group, Myrtle Beach, SC, 1999 - present
• Chief of Staff, Grand Strand Regional Medical Center, Myrtle Beach, SC, January 2001 to January 2002
• Vice Chief of Staff, Grand Strand Regional Medical Center, Myrtle Beach, SC, January 2000 to January 2001
• Secretary/Treasurer Medical Staff, Grand Strand Regional Medical Center, Myrtle Beach,
  SC, January 1991 to January 2001
• Chairman, Department of Surgery, Grand Strand Regional Medical Center, Myrtle Beach, SC, January 1997 to January 1998
• Vice Chairman, Department of Surgery, Grand Strand Regional Medical Center, Myrtle Beach, SC, 1996 to 1997
• Chairman, Carolina Lithotripsy, LLC, Myrtle Beach, SC, January 1997 to January 2004
• Private Practice Editorial Board, UROLOGY TIMES, 7500 Old Oak Boulevard, Cleveland, Ohio, December 1999 - present
• Medical Advisory Committee, South Strand Ambulatory Care Center, Myrtle Beach, SC, 1997 to 2002
• Amgen Praecis Prostate Cancer Advisory Board, Clinical Consultant, Creation CME program Prostate Cancer, January 2000
• Two Against One.com, Board of Directors, National web site promoting treatment and understanding Prostate Cancer
• Celsion Medical Advisory Board, 2001- present
• DepoMed Inc., Medical Advisory Board, 2001- present
• ProUrocare, Medical Advisory Board, 2001- present
• Dendreon Medical Advisory Board, December 2003 - present
• ACMI- CoreTherm Medical Advisory Board, 2002 - present
• QLT Medical Advisory Board, March 2004 - present
• Clinical Consultant for Cryosurgery, Oncura USA, University of Virginia Medical Center, Stoneybrook Medical Center, Long Island, NY, Mentefiore Medical Center, NY, Duke University Medical Center, Durham, NC, University of Chicago Medical Center, Illinois, Moffett Cancer Center, Tampa Florida, Baylor Hospital, Houston, Texas
• Praecis, National Cancer Advisory Board, 2004 - Present

Associations

• American College of Surgeons
• American Urological Association
• American Medical Association
• Florida Urological Society, Honarary Member, March 2005
• South Carolina Medical Society
• Big Brothers Horry County, Board of Directors, 1998-1999
• Sertoma Club, Board of Director, President 2000-2001
• Burroughs & Chapin Art Museum, Board of Directors, 2000-2002
• Brookgreen Gardens, President's Council, 2000-present
• Morley Foundation, Clinical Trials Training for Medical Professionals: October, 2002
• ACRP
• DIA
• NCI - NIH Human Participants Protection Education for Research Teams, October 2004
• OHRP Human Subject Assurance Training, October 2004.
  

^ Back to top

Lectures and Presentations

• Abarelix Crossover Study-Open Label Study to evaluate the feasibility of switching to treatment with a LH/RH agonist following 12 weeks of treatment with Abarelix in patients with Prostate Cancer, Protocol # 149-01-04, Principal Investigator.
• Abarelix Study Protocol 149-01-05-Open Label Comparison of Neoadjuvant Hormonal Therapy with Abarelix or Lupron in patients with Prostate Cancer planning to undergo Brachytherapy or External Beam Radiation Therapy, 3 B Trial, Principal Investigator.
• Amgen, An open-label comparison of Neoadjuvant Hormonal Therapy with Abarelix Depot 100 mg IM or Lupron Depot 7.5 mg IM in patients with Prostate Cancer planned to undergo Brachytherapy or External-Beam Radiation Therapy, Principal Investigator.
• Atrix -12 month, open-label evaluating LA-2580 45 mg, Prostate Cancer, Principal Investigator.
• Celsion - Liposome Study, A Dose Escalating, Pharmacokinetics, and Safety Study of Doxorubicin Encapsulated in Temperature Sensitive Liposomes Released Through Microwave Therapy in the Treatment of Prostate Cancer, Principal Investigator.
• Dendreon - An Open Label, Single Arm Trial of Immunotherapy with Autologous Antigen Presenting Cells with PA2024 (APC8015F) for Subjects with objective Disease Progression and Disease-Related Pain on Protocol D9902 Part B, Principal Investigator.
• Hydromed Sciences, Phase III-Open Label Study to evaluate efficacy and safety of Histrelin Subdermal Implant in-patient with advanced Prostate Cancer, Principal Investigator.
• Medarex - A Randomized Study Comparing 4 Monthly Doses of MDX-010 as a Single Agent or Used in Combination with a Single Dose of Docetaxel in Patients with Hormone-Refractory Prostate Cancer, Sub-Investigator.
• NMP-48, Multi-site Clinical Trial to investigate the performance (sensitivity and specificity) of NMP-48 test in detecting Prostate Cancer.
• Novartis - Zometa US24 Study, The Effect of Zometa Compared to Placebo on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy.
• Novartis - Zometa US 45 Study, The Effect of Zometa 4 mg. On Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients with Bone Metastasis.
• Prospective Randomized Comparison of Lupron, Flutamide, Finasteride, Neoadjuvant/Adjuvant Hormone Therapy in Men with Localized Carcinoma of the Prostate, Principal Investigator, Nelson Stone, MD, Mount Sinai Medical Center, New York, NY.
• Sanofi-Synthelabo Inc., - Prospective, Observational Registry of the Management of Men with Prostate Cancer and a Rising PSA following Definitive Surgical or Radiological Treatment of the Primary Tumor: PCA Registry COMPARE (Comprehensive, Observational, Multicenter Prostate Adenocarcinoma Registry), Principal Investigator.
• TAP Pharmaceuticals - Phase III- Six month Depot Formulation of Leuprolide Acetate in Subjects with Prostate Cancer, Principal Investigator.
• Tap Pharmaceuticals Randomized Prospective Study Adjuvant Androgen Ablation in Radical Prostatectomy patients at high risk for recurrence, Principal Investigator.
• Yamanouchi - A Randomized, Double Blind, Placebo-Controlled, Parallel Group, Pilot Study to Assess the Efficacy, Safety and Tolerability of YM598 in Combination with Mitoxantrone and Prednisone versus Placebo, Mitoxantrone and Prednisone in Androgen-independent Prostate Cancer (AIPC) Patients with Bone Pain, Principal Investigator.

BLADDER CANCER

• National Phase II Trial of Interferon, Alpha-Plus, BCG for treatment of superficial Bladder Cancer, Brigham
• Women's Hospital, Boston, MA, Principal Investigator, Michael O'Donnell, MD, Regional Principal Investigator.
• National Phase III Trial Interferon, BCG and Vitamins for treatment of superficial Bladder Cancer, University of West Virginia, Principal Investigator, Donald Lamm, MD, Regional Principal Investigator.

DEVICE STUDIES

• Abbeymoor - Prospective, Randomized, Controlled Study Comparing the Use of Temporary Prostatic Uretheral Stent after Transurethral Microwave Therapy (TUMT), Principal Investigator.
• AMS 021 - Evaluation of an Absorbable Urethral Stent after Microwave Therapy, Principal Investigator.
• Celsion Microwave Thermotherapy Medical Device Trial, BPH Phase II Study, Principal Investigator.
• Silimed, Inc., Testicular Implant Clinical Trial Study, Principal Investigator.

VOIDING DISORDERS

• Assessment of the efficacy of Tolterodine ER verses Placebo for the symptom of urgency and the improvement in bladder condition, Principal Investigator.
• IMPACT 2001, estrogen Vaginal Cream Study regarding Atrophic Vaginitis and Irritable Bladder Symptoms.
• Indevus - Double-Blind Placebo-Controlled Study of Urinary Urgency Using Trospium Chloride 20 mg tablets twice daily for 12 weeks, followed by a 6-month - open label for OAB, Sub-Investigator.
• Kyowa, a 6-week study of efficacy and safety of KW-7158 in-patient with an overactive bladder, Principal Investigator.
• Yamanouchi - Open Label Study of the Efficacy and Safety of 5 and 10 Vesicare® in Patients with Overactive Bladder Symptoms, Principal Investigator.

BPH TRIALS

• AMS 022, Characterization of the Prostatic Urethra in Patients with BPH after TUMT, Principal Investigator.
• Armed, LLC, Medical Technology regarding Prostate Disease evaluation, 10201 Wayzata Boulevard, Suite 150, Minneapolis, MN 55305, Principal Investigator.
• Celsion - BPH Phase II Study - TUMT with Proscar for History of BPH, Principal Investigator.
• Nymox, NX -1207, A Phase I Controlled, Randomized Escalating Dose Tolerance Study, given by Intraprostatic Injection in BPH Patients. Principal Investigator.
• QLT Inc. - A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Transurethral Photodynamic Therapy with QLT0074 for Benign Prostatic Hyperplasia, Principal Investigator.
• Sanofi-Synthelabo, Inc., - Prospective, Observational Registry and Patient Survey of the Management of Men with Symptomatic Benign Prostatic Hyperplasia (BPH): BPH Registry and Patient Survey, Principal Investigator.

OTHER

• DepoMed - Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy of Ciprofloxin Gastric Retentive (GR) QD and Ciprofloxin Immediate Releast (IR) BID for the Treatment of Uncomplicated UTI, Principal Investigator.
• Elevated PSA/Biopsy Study, Clinical Investigator, Bioclinical Partners, Diagnostic Support Services, 28 Jan Sebastian Way, PO Box 738, Forestdale, MA 02644, Principal Investigator.
• Impath Predictive Oncology, A multi-center study of patients with Non-metastatic Renal Cell Carcinoma and Bladder Carcinoma and occult cancer cells in the blood, Principal Investigator.
• Integrated Therapeutics Group, Inc., Oncology/Biotech Project Management, 3816 Sweeten Creek Road, Chapel Hill, NC 27514, Clinical Investigator.
  

^ Back to top